GlassScriptPhysician profile
Nikoletta Sidiropoulos
NPI 1356446017
$51,282.75
in general payments reported to CMS, 2019-2025
6 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Molecular Genetic Pathology (Medical Genetics) provider received nationally (typical 2025 total: $143).
See the full distribution for Molecular Genetic Pathology (Medical Genetics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $9,518 · 2021: $9,965 · 2022: $1,593 · 2024: $12K · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,138 · Consulting Fee: $4,778 · Travel and Lodging: $604 · Food and Beverage: $447 · Gift: $2.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,137.50 |
| Consulting Fee | $4,777.50 |
| Travel and Lodging | $604.23 |
| Food and Beverage | $447.34 |
| Gift | $2.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,674.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $14,004.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $10,585.20 | 2020-2021 | |
| Illumina, INC. | $6,236.78 | 2024 | Oncology Testing |
| Astrazeneca Pharmaceuticals LP | $5,732.69 | 2024-2025 | Imfinzi, Tagrisso |
| Genentech, INC. | $49.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikoletta Sidiropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.